文献检索
文档翻译
深度研究
Zotero 插件
邀请有礼
套餐&价格
历史记录
Suppr
超能文献
应用&插件
FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer.
出版信息
J Nucl Med. 2022 May;63(5):13N.
PMID:
35487569
Abstract
摘要
文献AI研究员
20分钟写一篇综述，助力文献阅读效率提升50倍。
立即体验
用中文搜PubMed
大模型驱动的PubMed中文搜索引擎
马上搜索
文档翻译
学术文献翻译模型，支持多种主流文档格式。
立即体验
应用&插件
Zotero 插件
浏览器插件
Mac 客户端
Windows 客户端
微信小程序
定价
高级版会员
购买积分包
购买API积分包
服务
文献检索
文档翻译
深度研究
API 文档
关于我们
关于 Suppr
公司介绍
联系我们
用户协议
隐私条款
关注我们
Suppr 超能文献
核心技术专利：
CN118964589B
侵权必究
粤ICP备2023148730 号-1
Suppr @ 2025
相似文献
1
FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2022 May;63(5):13N.
2
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
Clin Adv Hematol Oncol. 2015 May;13(5):293-8.
3
Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
Clin Adv Hematol Oncol. 2015 May;13(5):293-5.
4
Metastatic castration-resistant prostate cancer therapy: the quest for the perfect molecule.
Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):883-884. doi: 10.1007/s00259-023-06506-8.
5
[Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.
6
Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223.
Clin Genitourin Cancer. 2017 Jun;15(3):e501-e502. doi: 10.1016/j.clgc.2016.12.028. Epub 2016 Dec 29.
7
Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.
8
Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing Lu-PSMA Therapy.
J Nucl Med. 2018 Jul;59(7):1033-1034. doi: 10.2967/jnumed.118.209270. Epub 2018 Apr 13.
9
[The modern treatment of metastatic castration-resistant prostate cancer].
Magy Onkol. 2019 Mar 19;63(1):41-50. Epub 2019 Jan 2.
10
Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG.
Crit Rev Oncol Hematol. 2018 Feb;122:144-149. doi: 10.1016/j.critrevonc.2017.12.012. Epub 2017 Dec 30.
引用本文的文献
1
Evaluating the Potential of PSMA Targeting in CNS Tumors: Insights from Large-Scale Transcriptome Profiling.
Cancers (Basel). 2025 Apr 6;17(7):1239. doi: 10.3390/cancers17071239.
2
Interactions between key genes and pathways in prostate cancer progression and therapy resistance.
Front Oncol. 2025 Jan 23;15:1467540. doi: 10.3389/fonc.2025.1467540. eCollection 2025.
3
Safety, Dosimetry, and Feasibility of [Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer.
J Nucl Med. 2025 Mar 3;66(3):359-365. doi: 10.2967/jnumed.124.268318.
4
Novel astatine (At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model.
Eur J Nucl Med Mol Imaging. 2025 Jan;52(2):469-481. doi: 10.1007/s00259-024-06945-x. Epub 2024 Oct 12.
5
Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?
Ther Adv Med Oncol. 2024 Oct 7;16:17588359241258367. doi: 10.1177/17588359241258367. eCollection 2024.
6
Unveiling the Potential of Prostate-Specific Membrane Antigen for Precision Diagnosis and Therapy of Prostate Cancer: A Radiopharmaceutical Perspective.
Malays J Med Sci. 2024 Aug;31(4):213-217. doi: 10.21315/mjms2024.31.4.17. Epub 2024 Aug 27.
7
PSMA-Targeted 2-Deoxyglucose-Based Dendrimer Nanomedicine for the Treatment of Prostate Cancer.
Biomacromolecules. 2024 Sep 9;25(9):6164-6180. doi: 10.1021/acs.biomac.4c00878. Epub 2024 Aug 20.
8
Synthesis of Cu-, Co-, and Ga-Labeled Radiopharmaceuticals Targeting Neurotensin Receptor-1 for Theranostics: Adjusting In Vivo Distribution Using Multiamine Macrocycles.
J Nucl Med. 2024 Aug 1;65(8):1250-1256. doi: 10.2967/jnumed.124.267469.
9
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice.
Exp Hematol Oncol. 2024 Mar 1;13(1):26. doi: 10.1186/s40164-024-00493-8.
10
Optimization and scale up of production of the PSMA imaging agent [F]AlF-P16-093 on a custom automated radiosynthesis platform.
EJNMMI Radiopharm Chem. 2024 Feb 23;9(1):15. doi: 10.1186/s41181-024-00247-1.
Zotero 插件